Medical Devices

Kiniksa raises its 2026 ARCALYST forecast after a blowout quarter, using its financial strength to advance a pipeline aimed at redefining pericarditis care.

Newbury's OSSC gains exclusive UK access to hyper-realistic spinal simulators, heralding a major shift from cadavers to advanced, risk-free training.

As it preps a first-in-human study for a deadly genetic heart disease, Nuevocor brings on gene therapy veteran Dr. Monica Shah to lead the charge.

Ascidian Therapeutics to present first human safety data for its Stargardt disease drug, a new RNA editing technology with broad potential for genetic diseases.

Moving beyond quick fixes, Alma unveils a continuous care strategy focused on long-term skin performance, signaling a major shift for the aesthetics industry.

Biotech firm Tr1X unveils promising data for its novel cell therapies, offering a scalable new approach to treating autoimmune diseases like MS and GvHD.

Umoja Biopharma's UB-VV500 aims to revolutionize myeloma care by creating a dual-antigen CAR T therapy directly inside the patient's body.

VisionSys AI is in talks for a massive $90M investment to pivot to BCI tech, but with its stock down 96%, can this lifeline conquer the final frontier?

New Phase 2a data reveals Oruka Therapeutics' ORKA-001 achieved complete skin clearance in nearly two-thirds of patients, positioning it as a potential game-changer.

A new report reveals payers are rewriting drug benefit rules, sacrificing rebates for more control as they grapple with the high cost of new therapies.

With investments exceeding $1B, PCI Pharma Services is expanding its US sterile manufacturing, tackling supply chain risks and boosting domestic production.

WACKER is set to reveal a cost-saving XRF testing method and a breakthrough gamma-sterilizable medical adhesive, poised to impact two key sectors.

A Calgary startup's revolutionary wound care gel, already used in hospitals, is now being funded by the government for battlefield trauma applications.

A financially struggling healthcare firm makes a bold leap into neurotechnology, but can it compete with giants like Neuralink in the high-risk BCI race?

A new long-term deal for the INTERCEPT system highlights a critical shift towards proactive pathogen reduction to protect France's blood supply from global threats.

Swiss medtech vVARDIS secures a major Apollo investment, valuing it over $1B for its revolutionary non-invasive cavity treatment, Curodont™.

The medtech firm's Series B will advance its smart nerve stimulation system, which uses real-time biological feedback to offer personalized chronic pain therapy.

A major trial shows once-weekly rezafungin is as effective as daily drugs for preventing deadly fungal infections, heralding a new era for patient care.

RedHill Biopharma flips a capital deficit to positive equity, driven by savvy partnerships for its drugs Talicia and Bekinda and a promising R&D pipeline.

The company's SEAL™ device, targeting complex wide-neck aneurysms, completes its final submission, backed by a major US clinical trial.